Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company that describes itself as pioneering cell therapy for autoimmune diseases. Its news flow centers on the development of its lead CAR-T candidate, Descartes-08, and its next-generation CAR-T program, Descartes-15. Company press releases highlight clinical trial milestones, regulatory designations, financial updates and corporate governance changes that are relevant for followers of RNAC news.
A major focus of Cartesian’s news is the Phase 3 AURORA trial of Descartes-08 in generalized myasthenia gravis (MG). Updates describe enrollment progress, prior Phase 2b data in MG, and the outpatient, no-preconditioning chemotherapy design of the AURORA trial. Additional news covers Descartes-08 development in systemic lupus erythematosus (SLE), including initial Phase 2 data, and the planned and ongoing expansion into myositis through a randomized, double-blind, placebo-controlled Phase 2 trial using a seamless adaptive design.
Cartesian also issues releases on pediatric autoimmune programs, such as a planned Phase 2 pediatric basket trial and the Phase 1/2 HELIOS pediatric trial, building on Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Other recurring RNAC news items include quarterly financial results with commentary on cash runway and research and development spending, employment inducement grants under its inducement plan, and board and executive changes documented in Form 8-K filings, such as the appointment of new directors and officers.
Investors and observers tracking RNAC news can expect coverage of clinical data readouts, trial initiations or pauses, regulatory designations, strategic prioritization of indications, and corporate governance developments. Bookmarking this page provides a centralized view of Cartesian’s press releases and related updates as the company advances Descartes-08 and Descartes-15 through clinical development in autoimmune disease and multiple myeloma.
Cartesian Therapeutics (NASDAQ: RNAC) said management will participate in investor conferences in March and April 2026, including a presentation at the 46th Annual TD Cowen Health Care Conference and fireside chats at Leerink and Needham.
Live webcasts and archived replays will be accessible in the Events section of the company website for a limited time.
Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options to two new employees on February 2, 2026. The awards total 12,050 options with an exercise price of $6.79 per share, equal to the Nasdaq closing price that day.
The options vest 25% on February 2, 2027, then monthly over 36 months, fully vesting February 2, 2030, and carry a ten-year term. Grants were approved by the board and made under Nasdaq Rule 5635(c)(4) as inducements to employment.
Cartesian Therapeutics (NASDAQ: RNAC) reported progress on Descartes-08 and 2026 priorities. Enrollment is on track in the randomized, double-blind Phase 3 AURORA trial (~100 AChR Ab+ MG participants) using six once-weekly outpatient infusions without preconditioning; primary endpoint is ≥3-point MG-ADL improvement at Month 4. The FDA accepted an IND for a seamless adaptive Phase 2 myositis trial (TRITON) up to 50 participants with an interim analysis after 10 participants to inform a potential single pivotal trial in 1H26. A Phase 1/2 pediatric trial (HELIOS) in juvenile dermatomyositis has been initiated. Peer-reviewed Nature Medicine publications describe mechanism of action and 12-month durable responses; a biologic-naive subgroup (n=7) showed 57% minimal symptom expression at Month 6 sustained to Month 12 and a median prednisone dose reduction of 55% at Month 12. No CRS or ICANS reported. Cash runway is expected into mid-2027.
Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock option awards to two new employees granted on January 2, 2026. The company issued options to purchase an aggregate of 7,350 shares at an exercise price of $6.76, equal to the Nasdaq closing price on the grant date.
The options were granted under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan, approved by the board, vest 25% on January 2, 2027 and then in 36 equal monthly installments, fully vesting on January 2, 2030, and have a ten-year term. Grants were made under Rule 5635(c)(4) of the Nasdaq Listing Rules.
Cartesian Therapeutics (NASDAQ: RNAC) announced the appointment of Adrian Bot, M.D., Ph.D. to its Board of Directors effective Dec. 18, 2025. Dr. Bot brings three decades of R&D experience in immune, cell, gene therapy and nanomedicines and will serve on the Board's Science and Technology Committee.
His background includes senior R&D roles at Capstan, Kite/Gilead, MannKind and Alliance Pharma, involvement with first-in-class CAR T development, and leadership in RNA-based precision medicines; he has co-authored >200 peer-reviewed works.
Cartesian Therapeutics (NASDAQ: RNAC) reported initial Phase 2 results for Descartes-08 in SLE showing a 100% LLDAS response at Month 3 among participants who reached that visit (n=3) and 2 of 3 DORIS remissions. Descartes-08 was well tolerated in the outpatient setting with no CRS or ICANS reported and statistically significant reductions (p<0.01) in several proinflammatory cytokines and plasmacytoid dendritic cells. The company will pause further SLE enrollment to prioritize Phase 3 myasthenia gravis and a planned seamless adaptive Phase 2-to-pivotal trial in myositis expected to start in 1H 2026, with an IND filing planned by end of 2025. Cash runway is expected to support operations through mid-2027.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 2025 results and clinical updates on Nov 6, 2025. The company reported $145.1 million in cash, cash equivalents and restricted cash as of Sept 30, 2025, which it expects will support operations into mid-2027, including completion of the Phase 3 AURORA trial.
Clinical highlights: enrollment is on track in the randomized Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody-positive myasthenia gravis (~100 participants; primary endpoint: ≥3-point MG-ADL improvement at Month 4), preliminary Phase 2 Descartes-08 SLE data expected by year-end, and a pediatric basket Phase 2 trial initiation expected by year-end; FDA granted Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Descartes-15 Phase 1 in multiple myeloma remains ongoing.
Financials: R&D $13.8M, G&A $7.7M for Q3 2025; net loss $35.9M, or $1.38 per share, vs. net loss $24.2M, or $1.13 per share in Q3 2024.
Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock-option awards to two new employees dated Oct 27, 2025 and Oct 29, 2025. One option covers 50,000 shares at an exercise price of $8.85 (closing price on Oct 27, 2025); the other covers 2,650 shares at an exercise price of $8.20 (closing price on Oct 29, 2025).
Both grants were approved by the board under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, vest 25% after one year then in three equal annual installments (fully vested in 2029), and carry a 10-year term. Grants were made under Nasdaq Rule 5635(c)(4) as inducements to employment.
Cartesian Therapeutics (NASDAQ: RNAC) announced that Carsten Brunn, Ph.D., currently President and CEO, was named Chairman of the Board effective October 29, 2025.
Dr. Brunn succeeds Carrie S. Cox, who is stepping down to focus on other responsibilities, including a recent appointment as Executive Chair of another publicly traded company. In connection with the change, Patrick Zenner, M.B.A. was named Lead Independent Director.
The company highlighted progress advancing Descartes-08 toward its first planned regulatory submission and referenced the board leadership transition as part of its corporate governance updates.
Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.
The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.